SLU-PP-332 (4 mg) is a higher-dose tablet format of the ERR\u03b1\/\u03b3 agonist exercise mimetic compound, supporting research protocols requiring higher doses or extended duration studies. This variant is particularly suited for investigations into the dose-dependent effects of ERR activation on metabolic gene transcription, muscle fiber-type transformation, mitochondrial adaptation, and endurance-related pathway activation. The 4 mg dose represents approximately 5\u00d7 the low-dose format, enabling researchers to explore the upper range of the dose-response curve and investigate potential ceiling effects or additional pathway engagement at higher ERR activation levels. Research applications include chronic exercise mimicry studies, combination therapy research with actual exercise protocols, muscle wasting and sarcopenia models, metabolic syndrome intervention studies, and comparative analysis with other exercise mimetic compounds (AICAR, GW501516). The tablet format facilitates oral administration in research protocols mimicking realistic delivery routes.<\/p>\n","protected":false},"excerpt":{"rendered":"
SLU-PP-332 (4 mg) is a higher-dose tablet format of the ERR\u03b1\/\u03b3 agonist exercise mimetic compound, supporting research protocols requiring higher doses or extended duration studies. This variant is particularly suited for investigations into the dose-dependent effects of ERR activation on metabolic gene transcription, muscle fiber-type transformation, mitochondrial adaptation, and endurance-related pathway activation. The 4 mg […]<\/p>\n","protected":false},"featured_media":192,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[25],"product_tag":[],"class_list":["post-193","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n